720-01-4

Basic information

• Product Name: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate
• Synonyms: 4-Chloro-2-trifluoromethyl-pyrimidine-5-carboxylic acid ethyl ester;Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate 97%;Ethyl4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate97%;4-chloro-6-ethyl-2-(trifluoroMethyl)pyriMidine-5-carboxylate;4-Chloro-5-(ethoxycarbonyl)-2-(trifluoromethyl)pyrimidine, 4-Chloro-5-(ethoxycarbonyl)-2-(trifluoromethyl)-1,3-diazine;Ethyl 4-chloro-2-(trifluoromethyl)-5-pyrimidinecarboxylate;ETHYL 4-CHLORO-2-(TRIFLUOROMETHYL)PYRIMIDINE-5-CARBOXYLATE;BUTTPARK 43\57-70
• CAS NO: 720-01-4
• Molecular Formula: C₈H₆ClF₃N₂O₂
• Molecular Weight: 254.59
• EINECS: 1592732-453-0
• Product Categories: Esters;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines;Fluorine series
• Mol File: 720-01-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 36 °C
• Boiling Point: 95 °C
• Flash Point: 93.292 °C
• Appearance: /
• Density: 1.449 g/cm³
• Vapor Pressure: 0.065mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.91±0.29(Predicted)
• CAS DataBase Reference: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(720-01-4)
• EPA Substance Registry System: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(720-01-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37/39
• Hazardous Substances Data: 720-01-4(Hazardous Substances Data)

Usage

General Description

Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is a chemical compound with the molecular formula C8H6ClF3N2O2. It is a pyrimidine derivative with a chloro substitution at the 4-position and a trifluoromethyl group at the 2-position. The ethyl ester of the carboxylic acid group is attached to the 5-position of the pyrimidine ring. Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is commonly used in the pharmaceutical industry as a building block for the synthesis of various pharmaceutical products. It has also been studied for its potential biological and pharmacological activities, including antiviral and anticancer properties. Overall, ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is a valuable compound with diverse applications in drug discovery and development.

InChI:InChI=1/C8H6ClF3N2O2/c1-2-16-6(15)4-3-13-7(8(10,11)12)14-5(4)9/h3H,2H2,1H3

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 343-67-9 ethyl 2-(trifluoromethyl)-1,6-dihydro-6-oxopyrimidine-5-carboxylate 
• 343-67-9 ethyl 4-hydroxy-2-trifluoromethylpyrimidine-5-carboxylate 

Downstream Products

• 306960-77-0 2-(trifluoromethyl)pyrimidine-5-carboxylic acid 
• 141872-40-4 ethyl 2-trifluoromethyl-4-{N-butyl-N-[(2'-[N-triphenylmethyl-1H-tetrazol-5-yl]biphenyl-4-yl)methyl]amino}pyrimidine-5-carboxylate 
• 1514-01-8 4-amino-5-(hydroxymethyl)-2-(trifluoromethyl)pyrimidine 
• 304693-64-9 ethyl 2-(trifluoromethyl)pyrimidine-5-carboxylate 

Relevant articles and documents

BENZAMIDE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a benzamide derivative compound, a method for preparing the same, and a pharmaceutical composition for treating or preventing an inflammatory disease containing the same as an active ingredient. The benzamide derivative compound according to the present invention inhibits the expression of PDE4 and regulates the expression of an inflammatory disease-related substance such as IL-4 (interleukin-4), IL-5 (interleukin-4), IFN-γ (interferon-γ), IL-17 (interluekin-17), IgE (immunoglobulin E), and TNF-α (tumor necrosis factor-α), and thus may be utilized as a pharmaceutical composition for treating or preventing an inflammatory disease.

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.

Novel inhibitors of AP-1 and NF-κB mediated gene expression: Structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylate

In an effort to identify novel inhibitors of AP-1 and NF-κB mediated transcriptional activation, several analogues of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylate (1) were synthesized and tested in two in vitro assays. The 2-(2'-thienyl) substituted compound (11) was identified as the most potent in this series. (C) 2000 Elsevier Science Ltd. All rights reserved.